A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma
Phase 1 Recruiting
453 enrolled
A Clinical Study of SHR-9539 in Patients With Multiple Myeloma
Phase 1 Recruiting
138 enrolled
A Study Evaluating Single-agent Inavolisib, Inavolisib Plus Atezolizumab, and Inavolisib Plus Pembrolizumab in PIK3CA-Mutated Cancers
Phase 1 Recruiting
30 enrolled
A First-in-Human (FIH) Study of BG-C137, an Anti-Fibroblast Growth Factor Receptor 2b (FGFR2b) Antibody Drug Conjugate, in Participants With Advanced Solid Tumors
Phase 1 Recruiting
168 enrolled
Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of TGW101 in Participants With Advanced Solid Tumors
Phase 1 Recruiting
50 enrolled
inMMyCAR
Phase 1 Recruiting
40 enrolled
A Study of KIVU-107 in Participants With Locally Advanced or Metastatic Solid Tumors
Phase 1 Recruiting
76 enrolled
Evaluation of Xaluritamig in Adults, Adolescents and Children With Relapsed or Refractory Ewing Sarcoma (EWS)
Phase 1 Recruiting
50 enrolled
A Clinical Study on the Safety, Tolerability, Pharmacokinetics and Efficacy of SHR-1049 in Patients With Advanced Solid Tumors
Phase 1 Recruiting
200 enrolled
A Study of GEN1106 in Participants With Solid Tumors
Phase 1 Recruiting
103 enrolled
A Phase 1, Open-label Trial of Belzupacap Sarotalocan (AU-011) in Bladder Cancer
Phase 1 Recruiting
55 enrolled
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors
Phase 1 Recruiting
450 enrolled
CLINCH
Phase 1 Recruiting
156 enrolled
A Study of NT-175 in Adult Subjects With Unresectable, Advanced, and/or Metastatic Solid Tumors That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation
Phase 1 Recruiting
45 enrolled
BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors
Phase 1 Recruiting
399 enrolled
Phase 1a/1b First-in-Human Study of BG-C9074 Alone and in Combination With Other Anticancer Therapies in Patients With Advanced Solid Tumors
Phase 1 Recruiting
308 enrolled
Open-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer
Phase 1 Recruiting
350 enrolled
A Phase 1 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors
Phase 1 Recruiting
140 enrolled
A Study to Evaluate the Safety, Tolerability, and Efficacy of Escalating Doses of BMS-986463 in Participants With Select Advanced Malignant Tumors.
Phase 1 Recruiting
240 enrolled
DELTA-101
Phase 1 Recruiting
396 enrolled
A Study of BG-C477 in Participants With Advanced Solid Tumors
Phase 1 Recruiting
310 enrolled
Anti-GD2 ADC M3554 in Advanced Solid Tumors
Phase 1 Recruiting
52 enrolled
BANTAM-01
Phase 1 Recruiting
148 enrolled
A Study of BGB-B455 in Adults With Advanced or Metastatic Solid Tumors
Phase 1 Recruiting
90 enrolled
A Study to Test Whether Treatment With BI 770371 in Combination With Pembrolizumab With or Without Cetuximab Helps People With Head and Neck Cancer Compared With Pembrolizumab Alone
Phase 1 Recruiting
90 enrolled
A Phase 1 Study of IM-1021 in Participants With Advanced Cancer
Phase 1 Recruiting
117 enrolled
Study of Orally Administered MOMA-341 in Participants With Advanced or Metastatic Solid Tumors
Phase 1 Recruiting
132 enrolled
Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of BL-M05D1 in Subjects With Solid Tumors
Phase 1 Recruiting
160 enrolled
A Study to Find a Suitable Dose of ASP5834 in Adults With Solid Tumors
Phase 1 Recruiting
364 enrolled
A First-in-Human Study of BG-C0902 Alone and in Combination With Other Therapeutic Agents in Patients With Advanced Solid Tumors
Phase 1 Recruiting
63 enrolled
An Investigational Study of BG-75202 Alone and in Combination With Other Therapeutic Agents in Adults With Advanced Solid Tumors
Phase 1 Recruiting
86 enrolled
A Study in People With Advanced Cancer (Solid Tumours) to Test Different Doses of BI 3810944 and to Find Out Whether it Helps
Phase 1 Recruiting
69 enrolled
A Study of BG-75098 Alone and in Combination With Other Agents in Adults With Advanced Solid Tumors
Phase 1 Recruiting
105 enrolled
A Study to Investigate the Effect of Capivasertib on the Pharmacokinetics of Oral Dextromethorphan (CYP2D6 Substrate) in Healthy Participants
Phase 1 Recruiting
42 enrolled
First-in-Human Study of ADCE-B05 in Patients With Advanced Solid Tumors
Phase 1 Recruiting
180 enrolled
A Study to Test Different Doses of BI 3923948 Alone and in Combination With an Anti-PD-1 Antibody in People With Different Types of Advanced Cancer (Solid Tumors)
Phase 1 Recruiting
60 enrolled
Study of INCA036978 in Participants With Myeloproliferative Neoplasms
Phase 1 Recruiting
218 enrolled
DXP-106
Phase 1 Recruiting
54 enrolled
A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
Phase 1 Recruiting
572 enrolled
LuCa-MERIT-1
Phase 1 Recruiting
320 enrolled
A Study to Test Different Doses of BI 1831169 Alone and in Combination With an Anti-PD-1 Antibody in People With Different Types of Advanced Cancer (Solid Tumors)
Phase 1 Recruiting
190 enrolled
Study of INCB123667 in Subjects With Advanced Solid Tumors
Phase 1 Recruiting
604 enrolled
A Study of XMT-1660 in Participants With Solid Tumors
Phase 1 Recruiting
319 enrolled
A Study of ASP3082 in Adults With Advanced Solid Tumors
Phase 1 Recruiting
681 enrolled
GT101 Injection for the Treatment of Metastatic or Recurrent Solid Tumors
Phase 1 Recruiting
31 enrolled
Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Phase 1 Recruiting
171 enrolled
FIT-001
Phase 1 Recruiting
300 enrolled
A Study of JNJ-88549968 for the Treatment of Calreticulin (CALR)-Mutated Myeloproliferative Neoplasms
Phase 1 Recruiting
220 enrolled
SNV1521 in Participants With Advanced Solid Tumors
Phase 1 Recruiting
400 enrolled
SynKIR-310 for Relapsed/Refractory B-NHL
Phase 1 Recruiting
36 enrolled